kynurenine has been researched along with Astrocytoma, Grade IV in 14 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified tryptophan, methionine, kynurenine, and 5-methylthioadenosine as differentially regulated metabolites (DRM) in glioblastoma cells compared with normal human astrocytes (NHAs)." | 7.83 | Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation. ( Bassett, E; Chakravarti, A; Fischer, SM; Gordon, N; Jacob, JR; Kanji, S; Lautenschlaeger, T; Litzenberg, KT; Palanichamy, K; Patel, D; Ramasubramanian, B; Ray-Chaudhury, A; Sebastian, N; Singh, R; Thirumoorthy, K, 2016) |
| "We hypothesized that peripheral tryptophan (Trp) and/or kynurenine (Kyn) levels would provide prognostic value for physicians planning to enroll glioblastoma multiforme (GBM) patients in immunotherapy." | 7.81 | The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. ( Bloch, O; Dey, M; Dostal, CR; Gritsina, G; Kaur, R; Lauing, KL; Lukas, RV; McCusker, RH; Nicholas, MK; Parsa, AT; Rademaker, AW; Raizer, JJ; Wainwright, DA; Zhai, L, 2015) |
| " This study investigates the impact of 6'-bromoindirubin-3'-acetoxime (BiA) on immunosuppressive mechanisms in glioblastoma (GBM) and evaluates the efficacy of a BiA nanoparticle formulation, PPRX-1701, in immunocompetent mouse GBM models." | 4.31 | PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models. ( Boucher, P; Chiocca, EA; Finkelberg, T; Jimenez-Macias, JL; Koch, MS; Lawler, SE; Li, W; Ling, AL; Manz, KE; Nowicki, MO; Pennell, KD; Piranlioglu, R; Takeda, Y; Wu, B; Zdioruk, M, 2023) |
| " Here we report that kynurenine produced by glioblastoma cells activates aryl hydrocarbon receptor (AHR) in TAMs to modulate their function and T cell immunity." | 3.91 | Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. ( Antel, J; Barroso, A; Chao, CC; de Lima, KA; Farez, MF; Gabriely, G; Getz, G; Ghannam, S; Gutiérrez-Vázquez, C; Healy, L; Kenison, J; Mascanfroni, ID; Mayo, L; Prat, A; Quintana, FJ; Reardon, DA; Robson, SC; Rothhammer, V; Rothweiler, S; Sherr, D; Takenaka, MC; Tjon, EC; Vandeventer, T; Weiner, HL; Wheeler, MA; Zandee, S; Zhang, H, 2019) |
| " The AhR and its ligands also inhibit colon carcinogenesis, but it has been reported that the AhR and its ligand kynurenine enhance glioblastoma (GBM)." | 3.91 | The aryl hydrocarbon receptor is a tumor suppressor-like gene in glioblastoma. ( Cheng, Y; Jin, UH; Karki, K; Michelhaugh, SK; Mittal, S; Safe, S, 2019) |
| "We identified tryptophan, methionine, kynurenine, and 5-methylthioadenosine as differentially regulated metabolites (DRM) in glioblastoma cells compared with normal human astrocytes (NHAs)." | 3.83 | Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation. ( Bassett, E; Chakravarti, A; Fischer, SM; Gordon, N; Jacob, JR; Kanji, S; Lautenschlaeger, T; Litzenberg, KT; Palanichamy, K; Patel, D; Ramasubramanian, B; Ray-Chaudhury, A; Sebastian, N; Singh, R; Thirumoorthy, K, 2016) |
| "We hypothesized that peripheral tryptophan (Trp) and/or kynurenine (Kyn) levels would provide prognostic value for physicians planning to enroll glioblastoma multiforme (GBM) patients in immunotherapy." | 3.81 | The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. ( Bloch, O; Dey, M; Dostal, CR; Gritsina, G; Kaur, R; Lauing, KL; Lukas, RV; McCusker, RH; Nicholas, MK; Parsa, AT; Rademaker, AW; Raizer, JJ; Wainwright, DA; Zhai, L, 2015) |
| "The data indicate that, in mice with brain tumors, youth conveys an advantage to survival." | 1.43 | Advanced age negatively impacts survival in an experimental brain tumor model. ( Genet, M; Gritsina, G; James, CD; Ladomersky, E; Lauing, KL; Wainwright, DA; Wu, M; Zhai, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zdioruk, M | 1 |
| Jimenez-Macias, JL | 1 |
| Nowicki, MO | 1 |
| Manz, KE | 1 |
| Pennell, KD | 1 |
| Koch, MS | 1 |
| Finkelberg, T | 1 |
| Wu, B | 1 |
| Boucher, P | 1 |
| Takeda, Y | 1 |
| Li, W | 1 |
| Piranlioglu, R | 1 |
| Ling, AL | 1 |
| Chiocca, EA | 1 |
| Lawler, SE | 1 |
| Mohapatra, SR | 1 |
| Sadik, A | 1 |
| Tykocinski, LO | 1 |
| Dietze, J | 1 |
| Poschet, G | 1 |
| Heiland, I | 1 |
| Opitz, CA | 1 |
| Riess, C | 1 |
| Schneider, B | 1 |
| Kehnscherper, H | 1 |
| Gesche, J | 1 |
| Irmscher, N | 1 |
| Shokraie, F | 1 |
| Classen, CF | 1 |
| Wirthgen, E | 1 |
| Domanska, G | 1 |
| Zimpfer, A | 1 |
| Strüder, D | 1 |
| Junghanss, C | 1 |
| Maletzki, C | 1 |
| Sordillo, PP | 1 |
| Sordillo, LA | 1 |
| Helson, L | 1 |
| Kesarwani, P | 1 |
| Kant, S | 1 |
| Prabhu, A | 1 |
| Chinnaiyan, P | 1 |
| Takenaka, MC | 1 |
| Gabriely, G | 1 |
| Rothhammer, V | 1 |
| Mascanfroni, ID | 1 |
| Wheeler, MA | 1 |
| Chao, CC | 1 |
| Gutiérrez-Vázquez, C | 1 |
| Kenison, J | 1 |
| Tjon, EC | 1 |
| Barroso, A | 1 |
| Vandeventer, T | 1 |
| de Lima, KA | 1 |
| Rothweiler, S | 1 |
| Mayo, L | 1 |
| Ghannam, S | 1 |
| Zandee, S | 1 |
| Healy, L | 1 |
| Sherr, D | 1 |
| Farez, MF | 1 |
| Prat, A | 1 |
| Antel, J | 1 |
| Reardon, DA | 1 |
| Zhang, H | 1 |
| Robson, SC | 1 |
| Getz, G | 1 |
| Weiner, HL | 1 |
| Quintana, FJ | 1 |
| Jin, UH | 1 |
| Karki, K | 1 |
| Cheng, Y | 1 |
| Michelhaugh, SK | 2 |
| Mittal, S | 2 |
| Safe, S | 1 |
| Zhai, L | 3 |
| Dey, M | 1 |
| Lauing, KL | 3 |
| Gritsina, G | 3 |
| Kaur, R | 1 |
| Lukas, RV | 1 |
| Nicholas, MK | 1 |
| Rademaker, AW | 1 |
| Dostal, CR | 2 |
| McCusker, RH | 2 |
| Raizer, JJ | 1 |
| Parsa, AT | 1 |
| Bloch, O | 1 |
| Wainwright, DA | 3 |
| Bostian, AC | 1 |
| Maddukuri, L | 1 |
| Reed, MR | 1 |
| Savenka, T | 1 |
| Hartman, JH | 1 |
| Davis, L | 1 |
| Pouncey, DL | 1 |
| Miller, GP | 1 |
| Eoff, RL | 1 |
| Palanichamy, K | 1 |
| Thirumoorthy, K | 1 |
| Kanji, S | 1 |
| Gordon, N | 1 |
| Singh, R | 1 |
| Jacob, JR | 1 |
| Sebastian, N | 1 |
| Litzenberg, KT | 1 |
| Patel, D | 1 |
| Bassett, E | 1 |
| Ramasubramanian, B | 1 |
| Lautenschlaeger, T | 1 |
| Fischer, SM | 1 |
| Ray-Chaudhury, A | 1 |
| Chakravarti, A | 1 |
| Guastella, AR | 1 |
| Klinger, NV | 1 |
| Kupsky, WJ | 1 |
| Polin, LA | 1 |
| Muzik, O | 1 |
| Juhász, C | 1 |
| Ladomersky, E | 2 |
| Genet, M | 1 |
| Wu, M | 2 |
| James, CD | 1 |
| Swoap, K | 1 |
| Billingham, LK | 1 |
| Binder, DC | 1 |
| Boni, RL | 1 |
| Simpson, JT | 1 |
| Naritsin, DB | 1 |
| Saito, K | 1 |
| Markey, SP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas[NCT05768919] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for kynurenine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cytokines; Drug Resistance, Neoplasm; Glioblastoma; Humans; Indoleam | 2017 |
The interplay between metabolic remodeling and immune regulation in glioblastoma.
Topics: Glioblastoma; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Signal Transduction; Tryptop | 2017 |
12 other studies available for kynurenine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models.
Topics: Animals; Glioblastoma; Kynurenine; Mice; Oximes; Tryptophan | 2023 |
Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.
Topics: Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Glioblasto | 2019 |
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2020 |
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
Topics: Animals; Antigens, CD; Apyrase; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma | 2019 |
The aryl hydrocarbon receptor is a tumor suppressor-like gene in glioblastoma.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Female; Glioblastoma; Humans; Immunotherapy; Kynurenine; Male; Middl | 2015 |
Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells.
Topics: DNA-Directed DNA Polymerase; Enzyme Inhibitors; Genomic Instability; Glioblastoma; Humans; Indoles; | 2016 |
Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
Topics: Astrocytes; Biomarkers, Tumor; Carcinogenesis; Cell Line; Cell Proliferation; Chromatography, High P | 2016 |
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
Topics: Aged; Animals; Biosynthetic Pathways; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Femal | 2016 |
Advanced age negatively impacts survival in an experimental brain tumor model.
Topics: Aging; Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Glioblastoma; Indoleamine | 2016 |
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Topics: Animals; Brain; Brain Neoplasms; Disease Models, Animal; Glioblastoma; Indoleamine-Pyrrole 2,3,-Diox | 2017 |
Quantification of L-tryptophan and L-kynurenine by liquid chromatography/electron capture negative ion chemical ionization mass spectrometry.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Chromatography, Liquid; Fluorobenzen | 1994 |